Vax4eU Vaccinologists for Europe: Training network for developing next generation vaccines against mucosal pathogens
- Coordinator
- Technische Universitaet Muenchen, Germany
- Runs
- 1 February 2027 to 31 January 2031
- Status
- Running
- EU funding
- €4.6m
- Total cost
- —
- Partners
- 19 organisations in 9 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311814
What the project is doing
In the project's own words, from its summary on CORDIS.
AntimicrobiaAntimicrobial resistance (AMR) and emerging viral pathogens pose significant global health threats, with mucosal infections contributing to severe morbidity and mortality. Current systemic immunization strategies fail to induce effective mucosal immunity, including tissue-resident memory cells (TRMs) and secretory IgA (sIgA). Addressing this gap requires targeted research and training in mucosal vaccinology.
The Vax4eU network aims to advance next-generation mucosal vaccines through a multidisciplinary program for 16 Doctoral Candidates (DCs), focusing on vaccine candidates and technologies that induce robust mucosal immunity, prevent infection, and combat AMR.Vax4eU integrates cutting-edge approaches, including AI-assisted antigen design, novel adjuvants, and tailored nanoparticle delivery systems. Research spans the vaccine pipeline, from drug substance design to preclinical evaluation.
Work Package (WP) 1 focuses on antigens and adjuvants, using platforms like mRNA and fusion proteins, along with mucosal-targeting strategies such as ""Blood2Gut"" adjuvants. WP 2 develops advanced delivery systems, including polysaccharide, protein, and lipid nanoparticles and innovative mucosal adjuvants like cyclic dimeric AMP. WP 3 identifies CoIs and CoPs using high-dimensional tools and preclinical models, including pigs, which closely mimic human mucosal immunity.
The program combines research with robust training, offering DCs individualized projects, network-wide training in AI tools, regulatory processes, drug delivery, and preclinical studies. Collaboration with academic and non-academic partners ensures DCs gain insights into scientific and translational aspects of vaccinology, supported by secondments, expert mentoring, and interinstitutional collaboration. By advancing mucosal vaccine technology and addressing AMR, Vax4eU aligns with European public health priorities, fostering a new generation of skilled vaccinologists to tackle global infectious diseases.""
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Technische Universitaet Muenchen | Muenchen | Germany | Coordinator |
| Universiteit Antwerpen | Antwerpen | Belgium | Associatedpartner |
| Vib Vzw | Zwijnaarde - Gent | Belgium | Participant |
| Universitat Zurich | Zurich | Switzerland | Participant |
| Helmholtz-Zentrum Fur Infektionsforschung GmbH | Braunschweig | Germany | Participant |
| Linq Management GmbH | Berlin | Germany | Associatedpartner |
| Technische Universitaet Braunschweig | Braunschweig | Germany | Associatedpartner |
| Croda Denmark A/S | Frederikssund | Denmark | Associatedpartner |
| Evaxion | Hørsholm | Denmark | Associatedpartner |
| Kobenhavns Universitet | Kobenhavn | Denmark | Associatedpartner |
| Statens Serum Institut | Kobenhavn S | Denmark | Participant |
| Inmunotek SL | Alcala De Henares | Spain | Participant |
| Universidad Complutense De Madrid | Madrid | Spain | Associatedpartner |
| Universidad De Navarra | Pamplona | Spain | Participant |
| Institut Curie | Paris | France | Participant |
| Universite Paris Sciences Et Lettres | Paris | France | Associatedpartner |
| The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | Dublin | Ireland | Participant |
| Faculdade de Farmácia da Universidade de Lisboa | Lisboa | Portugal | Participant |
| University of Strathclyde | Glasgow | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI